Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient Demographics and Baseline Characteristics

From: Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Characteristics (N = 50)
Age, median (range), years 50.0 (21–71)
  < 65 years, n (%) 46 (92.0)
  ≥ 65 years, n (%) 4 (8.0)
Sex, n (%)
 Male 24 (48.0)
 Female 26 (52.0)
Geographic region, n (%)
 USA 27 (54.0)
 Europe 22 (44.0)
 Asia 1 (2.0)
ECOG PS, n (%)
 0 19 (38.0)
 1 31 (62.0)
Median time since first diagnosis (range), years 1.6 (0.2–15.1)
Median time since last disease progression (range), months 0.92 (0.33–8.61)
Number of prior lines of systemic anticancer therapy, n (%)
 1 13 (26.0)
 2 18 (36.0)
 3 10 (20.0)
  ≥ 4 9 (18.0)
Receiving concomitant mitotane, n (%) 25 (50.0)
PD-L1 expression on tumor cells (≥1% cutoff), n (%)
 Negative 27 (54.0)
 Positive 15 (30.0)
 Not evaluable 8 (16.0)
PD-L1 expression on tumor cells (≥5% cutoff), n (%)
 Negative 30 (60.0)
 Positive 12 (24.0)
 Not evaluable 8 (16.0)